{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:09:36Z","timestamp":1790212176688,"version":"4.1.0"},"reference-count":211,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2025.03564.BD"],"award-info":[{"award-number":["2025.03564.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115242","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:34:19Z","timestamp":1786059259000},"page":"115242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nanoengineered RNA delivery systems for gene therapy in intestinal fibrosis"],"prefix":"10.1016","volume":"398","author":[{"given":"B\u00e1rbara","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115242_bb0005","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.dld.2025.08.002","article-title":"Quantifying fibrosis in inflammatory bowel diseases \u2013 contribution of digital pathology","volume":"57","author":"Miha","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/CM9.0000000000003545","article-title":"Intestinal fibrosis associated with inflammatory bowel disease: known and unknown","volume":"138","author":"Zhang","year":"2025","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.jconrel.2026.115242_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/polym17060822","article-title":"Extracellular matrix stiffness: mechanotransduction and mechanobiological response-driven strategies for biomedical applications targeting fibroblast inflammation","volume":"17","author":"Tiskratok","year":"2025","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0020","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/nrm3896","article-title":"Mechanotransduction and extracellular matrix homeostasis","volume":"15","author":"Humphrey","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0025","series-title":"The Matrisome: An Emerging Regulator of Inflammation","author":"Quan","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115242_bb0030","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/gutjnl-2023-329963","article-title":"Fibrosis in IBD: from pathogenesis to therapeutic targets","volume":"73","author":"Rieder","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115242_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126326","article-title":"Fibrostenosing Crohn\u2019s disease: pathogenetic mechanisms and new therapeutic horizons","volume":"25","author":"Mignini","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115242_bb0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115242_bb0045","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41580-024-00716-0","article-title":"Fibroblast and myofibroblast activation in normal tissue repair and fibrosis","volume":"25","author":"Younesi","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2026.102917","article-title":"Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy","volume":"37","author":"Yang","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115242_bb0055","doi-asserted-by":"crossref","first-page":"eadu1493","DOI":"10.1126\/scitranslmed.adu1493","article-title":"Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease","volume":"17","author":"Huang","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41575-021-00543-0","article-title":"Revisiting fibrosis in inflammatory bowel disease: the gut thickens","volume":"19","author":"D\u2019Alessio","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0065","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5009\/gnl220045","article-title":"Cellular and molecular mechanisms of intestinal fibrosis","volume":"17","author":"Wu","year":"2023","journal-title":"Gut Liver"},{"key":"10.1016\/j.jconrel.2026.115242_bb0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/imr.12974","article-title":"Novel mechanisms and clinical trial endpoints in intestinal fibrosis","volume":"302","author":"Wang","year":"2021","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2026.115242_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115242_bb0080","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8190.1","article-title":"The myofibroblast in wound healing and fibrosis: answered and unanswered questions","volume":"5","author":"Bochaton-Piallat","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.jconrel.2026.115242_bb0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrgastro.2009.31","article-title":"Intestinal fibrosis in IBD\u2014a dynamic, multifactorial process","volume":"6","author":"Rieder","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0090","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/1751-2980.12852","article-title":"The fate of myofibroblasts during the development of fibrosis in Crohn\u2019s disease","volume":"21","author":"Li","year":"2020","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0095","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1097\/MIB.0b013e3182a8452e","article-title":"Increased activation of latent TGF-\u03b21 by \u03b1V\u03b23 in human Crohn\u2019s disease and fibrosis in TNBS colitis can be prevented by cilengitide","volume":"19","author":"Li","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fmed.2017.00103","article-title":"Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer","volume":"4","author":"Galdiero","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0105","article-title":"Mechanical and physical regulation of fibroblast-myofibroblast transition: from cellular mechanoresponse to tissue pathology","volume":"8","author":"D\u2019Urso","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0110","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41577-021-00540-z","article-title":"Fibroblasts as immune regulators in infection, inflammation and cancer","volume":"21","author":"Davidson","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0115","doi-asserted-by":"crossref","first-page":"13544","DOI":"10.1038\/s41598-018-31992-4","article-title":"Bioengineering functional smooth muscle with spontaneous rhythmic contraction in vitro","volume":"8","author":"Kobayashi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115242_bb0120","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/cvr\/cvy022","article-title":"Smooth muscle cell fate and plasticity in atherosclerosis","volume":"114","author":"Allahverdian","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb0125","first-page":"2457","article-title":"Contribution of intestinal smooth muscle to Crohn\u2019s disease fibrogenesis","volume":"58","author":"Severi","year":"2014","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.jconrel.2026.115242_bb0130","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/bjs.9302","article-title":"Circulating fibrocytes and Crohn\u2019s disease","volume":"100","author":"Sahebally","year":"2013","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.jconrel.2026.115242_bb0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10620-013-2813-8","article-title":"Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn\u2019s disease","volume":"59","author":"Sazuka","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.jconrel.2026.115242_bb0140","first-page":"1","article-title":"Circulating fibrocytes\u2014biology and mechanisms in wound healing and scar formation","volume":"291","author":"Grieb","year":"2011","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0145","doi-asserted-by":"crossref","first-page":"8568","DOI":"10.1038\/s41598-019-45012-6","article-title":"Infiltrating CCR2(+) monocytes and their progenies, fibrocytes, contribute to colon fibrosis by inhibiting collagen degradation through the production of TIMP-1","volume":"9","author":"Kuroda","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115242_bb0150","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/jcmm.12134","article-title":"Telocytes express PDGFR\u03b1 in the human gastrointestinal tract","volume":"17","author":"Vannucchi","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcdb.2016.01.022","article-title":"Telocyte implications in human pathology: an overview","volume":"55","author":"Ibba-Manneschi","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jcmm.12457","article-title":"Telocytes are reduced during fibrotic remodelling of the colonic wall in ulcerative colitis","volume":"19","author":"Manetti","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0165","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2026.115242_bb0170","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the T(H)1\/T(H)2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0180","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02442-2019","article-title":"Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Maher","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jconrel.2026.115242_bb0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0030-1255354","article-title":"Macrophages: master regulators of inflammation and fibrosis","volume":"30","author":"Wynn","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0190","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/mi.2015.123","article-title":"The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD","volume":"9","author":"Cos\u00edn-Roger","year":"2016","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0195","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/ibd\/izab029","article-title":"Human intestinal macrophages are involved in the pathology of both ulcerative colitis and Crohn disease","volume":"27","author":"Dharmasiri","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1755-1536-6-13","article-title":"The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis","volume":"6","author":"Biancheri","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.jconrel.2026.115242_bb0205","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/ecco-jcc\/jjw101","article-title":"Genetic deletion of tissue inhibitor of metalloproteinase-1\/TIMP-1 alters inflammation and attenuates fibrosis in dextran sodium sulphate-induced murine models of colitis","volume":"10","author":"Breynaert","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jconrel.2026.115242_bb0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clinre.2016.09.012","article-title":"Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients","volume":"41","author":"Zhu","year":"2017","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0215","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3389\/fphar.2019.01486","article-title":"Thalidomide prevented and ameliorated pathogenesis of Crohn\u2019s disease in mice via regulation of inflammatory response and fibrosis","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0220","first-page":"L344","article-title":"Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis","volume":"308","author":"Liu","year":"2015","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2026.115242_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/path.5680","article-title":"TGF-\u03b2 as a driver of fibrosis: physiological roles and therapeutic opportunities","volume":"254","author":"Budi","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0230","article-title":"The pivotal role of TGF-\u03b2\/Smad pathway in fibrosis pathogenesis and treatment","volume":"15","author":"Chen","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1113061","article-title":"TGF\u03b2 signaling pathways in human health and disease","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.jconrel.2026.115242_bb0240","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115242_bb0245","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/embor.2009.276","article-title":"Integrin\u2013TGF-\u03b2 crosstalk in fibrosis, cancer and wound healing","volume":"11","author":"Margadant","year":"2010","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jconrel.2026.115242_bb0250","first-page":"L1046","article-title":"Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis","volume":"303","author":"Naik","year":"2012","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2026.115242_bb0255","doi-asserted-by":"crossref","first-page":"G1324","DOI":"10.1152\/ajpgi.90564.2008","article-title":"Interleukin-1 participates in the progression from liver injury to fibrosis","volume":"296","author":"Gieling","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0260","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1568010033484296","article-title":"IL-6 and Crohn\u2019s disease","volume":"2","author":"Ito","year":"2003","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"10.1016\/j.jconrel.2026.115242_bb0265","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2133.2009.09215.x","article-title":"Interleukin (IL)-6 modulates transforming growth factor-beta expression in skin and dermal fibroblasts from IL-6-deficient mice","volume":"161","author":"Luckett-Chastain","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0270","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)","volume":"194","author":"Lee","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0275","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.4049\/jimmunol.178.9.5859","article-title":"Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis","volume":"178","author":"Fichtner-Feigl","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0280","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.2353\/ajpath.2010.100378","article-title":"Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts","volume":"177","author":"Sponheim","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0285","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0016-5085(93)90713-M","article-title":"Insulinlike growth factor I and interleukin 1 beta messenger RNA in a rat model of granulomatous enterocolitis and hepatitis","volume":"105","author":"Zimmermann","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb0290","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/mi.2010.67","article-title":"The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation","volume":"4","author":"Meylan","year":"2011","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0295","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2174\/187153007782794308","article-title":"Interleukin-21 (IL-21) controls inflammatory pathways in the gut","volume":"7","author":"Fina","year":"2007","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.jconrel.2026.115242_bb0300","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.4049\/jimmunol.1004081","article-title":"Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms","volume":"187","author":"Mi","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0305","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.4049\/jimmunol.1500777","article-title":"IL-21 promotes pulmonary fibrosis through the induction of profibrotic CD8+ T cells","volume":"195","author":"Brodeur","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0310","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.molimm.2011.12.004","article-title":"The role of IL-7 in renal proximal tubule epithelial cells fibrosis","volume":"50","author":"Hsieh","year":"2012","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0315","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/genes14061167","article-title":"The role of genetic and epigenetic regulation in intestinal fibrosis in inflammatory bowel disease: a descending process or a programmed consequence?","volume":"14","author":"Jarmakiewicz-Czaja","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.jconrel.2026.115242_bb0320","doi-asserted-by":"crossref","first-page":"1058237","DOI":"10.3389\/fimmu.2022.1058237","article-title":"Co-expression of fibrotic genes in inflammatory bowel disease; a localized event?","volume":"13","author":"Dovrolis","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0325","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13148-016-0193-6","article-title":"Genome-wide analysis of DNA methylation and gene expression defines molecular characteristics of Crohn\u2019s disease-associated fibrosis","volume":"8","author":"Sadler","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.jconrel.2026.115242_bb0330","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/MIB.0b013e318281f37a","article-title":"Cytokine-induced chromatin modifications of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition","volume":"19","author":"Sadler","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-026-00490-9","article-title":"Metabolic reprogramming in fibrosis-related diseases: underlying mechanisms and therapeutics","volume":"7","author":"Feng","year":"2026","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.jconrel.2026.115242_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.800747","article-title":"Complex involvement of the extracellular matrix, immune effect, and lipid metabolism in the development of idiopathic pulmonary fibrosis","volume":"8","author":"Qian","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.jconrel.2026.115242_bb0345","article-title":"Gut microbiota dysbiosis: pathogenesis, diseases, prevention, and therapy","volume":"6","author":"Shen","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0350","article-title":"Intestinal fibrosis in inflammatory bowel disease and the prospects of mesenchymal stem cell therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0355","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0360","first-page":"1283","article-title":"Can we prevent, reduce or reverse intestinal fibrosis in IBD?","volume":"17","author":"Latella","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2026.115242_bb0365","first-page":"186","article-title":"Current and emerging approaches to the diagnosis and treatment of Crohn\u2019s disease strictures","volume":"18","author":"Lee","year":"2022","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0370","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1751-2980.12880","article-title":"Surgical treatment of intestinal stricture in inflammatory bowel disease","volume":"21","author":"Mohan","year":"2020","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0375","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/jgh.14119","article-title":"Crohn\u2019s disease associated strictures","volume":"33","author":"Chan","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0380","first-page":"3213","article-title":"Risk of postoperative recurrence and postoperative management of Crohn\u2019s disease","volume":"17","author":"Spinelli","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40140-021-00493-y","article-title":"The hidden pandemic: the cost of postoperative complications","volume":"12","author":"Ludbrook","year":"2022","journal-title":"Curr. Anesthesiol. Rep."},{"key":"10.1016\/j.jconrel.2026.115242_bb0390","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.1994.tb00158.x","article-title":"Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn\u2019s disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)","volume":"8","author":"Caprilli","year":"1994","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.115242_bb0395","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/jgh3.12955","article-title":"Long-term safety and effectiveness of azathioprine in the management of inflammatory bowel disease: a real-world experience","volume":"7","author":"Yewale","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.jconrel.2026.115242_bb0400","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3748\/wjg.14.1885","article-title":"Effect of infliximab on small bowel stenoses in patients with Crohn\u2019s disease","volume":"14","author":"Pallotta","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0405","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","article-title":"Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study","volume":"67","author":"Bouhnik","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115242_bb0410","first-page":"Cd013611","article-title":"Vedolizumab for induction and maintenance of remission in Crohn\u2019s disease","volume":"7","author":"Hui","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jconrel.2026.115242_bb0415","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/apt.13361","article-title":"Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study","volume":"42","author":"Chhaya","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.115242_bb0420","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjad135","article-title":"Thiopurines have sustained long-term effectiveness in patients with inflammatory bowel disease, which is independent of disease duration at initiation: a propensity score matched analysis","volume":"18","author":"Ranjan","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.jconrel.2026.115242_bb0425","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/j.gastro.2021.12.083","article-title":"Endoscopic stricturotomy \u2013 a novel therapeutic modality for IBD-related strictures: first European experience","volume":"162","author":"Lukas","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb0430","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4253\/wjge.v8.i4.198","article-title":"Role of colonic stents in the management of colorectal cancers","volume":"8","author":"Sagar","year":"2016","journal-title":"World J. Gastrointest. Endosc."},{"key":"10.1016\/j.jconrel.2026.115242_bb0435","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.gie.2025.04.011","article-title":"Endoscopic balloon dilation for inflammatory bowel disease strictures: who benefits the most?","volume":"102","author":"Schwartz","year":"2025","journal-title":"Gastrointest. Endosc."},{"key":"10.1016\/j.jconrel.2026.115242_bb0440","article-title":"Advances in RNA therapeutics: classes, innovations and clinical applications","volume":"3","author":"Shahid","year":"2025","journal-title":"J. Precision Med. Health Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0445","article-title":"Circular RNAs in inflammatory bowel disease: a review of mechanisms, biomarkers and therapeutic potential","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112132","article-title":"Role of miRNA and lncRNAs in organ fibrosis and aging","volume":"143","author":"Ghafouri-Fard","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2026.115242_bb0455","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb0460","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0465","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ibd\/izac122","article-title":"MiRNA-based therapies for the treatment of inflammatory bowel disease: what are we still missing?","volume":"29","author":"Innocenti","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0470","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1111\/j.1523-1755.2000.00360.x","article-title":"Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction","volume":"58","author":"Isaka","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.jconrel.2026.115242_bb0475","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/jor.22890","article-title":"Development of antisense oligonucleotide (ASO) technology against Tgf-\u03b2 signaling to prevent scarring during flexor tendon repair","volume":"33","author":"Loiselle","year":"2015","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb0480","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.7","article-title":"Targeting TGF-\u03b2 signaling by antisense oligonucleotide-mediated knockdown of TGF-\u03b2 type I receptor","volume":"3","author":"Kemaladewi","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115242_bb0485","doi-asserted-by":"crossref","first-page":"17736","DOI":"10.1021\/acsanm.4c02996","article-title":"Antifibrotic and pro-regenerative effects of SMAD3 siRNA and collagen I mRNA-loaded lipid nanoparticles in human tenocytes","volume":"7","author":"L\u00f3pez-Cerd\u00e1","year":"2024","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.jconrel.2026.115242_bb0490","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymthe.2023.12.009","article-title":"Therapeutic potential for renal fibrosis by targeting Smad3-dependent noncoding RNAs","volume":"32","author":"Gu","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115242_bb0495","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/s44321-025-00283-7","article-title":"SMAD7: riding on fibrosis-limiting routes and beyond","volume":"17","author":"Martin","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0500","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1053\/j.gastro.2006.09.016","article-title":"Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis","volume":"131","author":"Boirivant","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb0505","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2011.290","article-title":"Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn\u2019s disease","volume":"20","author":"Monteleone","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.115242_bb0510","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0515","doi-asserted-by":"crossref","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","article-title":"Mongersen (GED-0301) for active Crohn\u2019s disease: results of a phase 3 study","volume":"115","author":"Sands","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0520","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1874312901206010130","article-title":"Role of MicroRNAs in fibrosis","volume":"6","author":"Vettori","year":"2012","journal-title":"Open Rheumatol. J."},{"key":"10.1016\/j.jconrel.2026.115242_bb0525","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/MIB.0000000000000298","article-title":"Intestinal fibrosis in Crohn\u2019s disease: role of microRNAs as fibrogenic modulators, serum biomarkers, and therapeutic targets","volume":"21","author":"Lewis","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0530","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1042\/CS20140048","article-title":"In Crohn\u2019s disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts","volume":"127","author":"Nijhuis","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0535","doi-asserted-by":"crossref","DOI":"10.31083\/j.fbl2811317","article-title":"MicroRNA in fibrotic disorders: a potential target for future therapeutics","volume":"28","author":"Mehjabin","year":"2023","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0540","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3892\/ijmm.2012.894","article-title":"miR-200b is involved in intestinal fibrosis of Crohn\u2019s disease","volume":"29","author":"Chen","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0545","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/jgh.13797","article-title":"miR-200b-containing microvesicles attenuate experimental colitis associated intestinal fibrosis by inhibiting epithelial-mesenchymal transition","volume":"32","author":"Yang","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0550","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.dld.2022.04.007","article-title":"MiR-21 regulates epithelial\u2013mesenchymal transition in intestinal fibrosis of Crohn\u2019s disease by targeting PTEN\/mTOR","volume":"54","author":"Wang","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0555","doi-asserted-by":"crossref","first-page":"i139","DOI":"10.1093\/ecco-jcc\/jjab232.135","article-title":"P006 MiR-192 is associated with structuring phenotype in Crohn\u2019s disease","volume":"16","author":"Cristina","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"10.1016\/j.jconrel.2026.115242_bb0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MIB.0000000000000618","article-title":"Novel PPAR\u03b3 modulator GED-0507-34 Levo ameliorates inflammation-driven intestinal fibrosis","volume":"22","author":"Speca","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0565","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.115242_bb0570","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1681\/ASN.2010111168","article-title":"Smad3-mediated upregulation of miR-21 promotes renal fibrosis","volume":"22","author":"Zhong","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0575","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/ijc.25506","article-title":"Micro-RNA-21 regulates TGF-\u03b2-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction","volume":"128","author":"Yao","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115242_bb0580","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbrc.2017.02.049","article-title":"NR2F2 inhibits Smad7 expression and promotes TGF-\u03b2-dependent epithelial-mesenchymal transition of CRC via transactivation of miR-21","volume":"485","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115242_bb0585","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1091\/mbc.e13-09-0560","article-title":"Inhibition of Smurf2 translation by miR-322\/503 modulates TGF-\u03b2\/Smad2 signaling and intestinal epithelial homeostasis","volume":"25","author":"Cao","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.jconrel.2026.115242_bb0590","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jcmm.12754","article-title":"MicroRNA-503 promotes angiotensin II-induced cardiac fibrosis by targeting Apelin-13","volume":"20","author":"Zhou","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0595","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/1933719115602768","article-title":"MicroRNA-29b inhibits endometrial fibrosis by regulating the Sp1-TGF-\u03b21\/Smad-CTGF axis in a rat model","volume":"23","author":"Li","year":"2016","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.jconrel.2026.115242_bb0600","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/annrheumdis-2019-216542","article-title":"Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH","volume":"79","author":"Wasson","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0605","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2020.00107","article-title":"miR-20a-5p\/TGFBR2 axis affects pro-inflammatory macrophages and aggravates liver fibrosis","volume":"10","author":"Fu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0610","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3390\/ijms20205084","article-title":"PGC-1\u03b1 suppresses the activation of TGF-\u03b2\/Smad signaling via targeting TGF\u03b2RI downregulation by let-7b\/c upregulation","volume":"20","author":"Choi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115242_bb0615","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1002\/jcp.29187","article-title":"WNT1-inducible signaling protein-1 mediates TGF-\u03b21-induced renal fibrosis in tubular epithelial cells and unilateral ureteral obstruction mouse models via autophagy","volume":"235","author":"Yang","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0620","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1007\/s10067-020-05554-x","article-title":"Glucocorticoid therapy suppresses Wnt signaling by reducing the ratio of serum Wnt3a to Wnt inhibitors, sFRP-1 and Wif-1","volume":"40","author":"Kawazoe","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0625","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tcb.2021.10.002","article-title":"Mechanical communication in fibrosis progression","volume":"32","author":"Long","year":"2022","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0630","article-title":"Extracellular matrix signaling cues: biological functions, diseases, and therapeutic targets","volume":"6","author":"Zhao","year":"2025","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100023","article-title":"Effects of cytokine signaling inhibition on inflammation-driven tissue remodeling","volume":"2","author":"Bignold","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.jconrel.2026.115242_bb0640","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s12276-020-00531-5","article-title":"Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway","volume":"52","author":"Ng","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115242_bb0645","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.ajpath.2015.02.018","article-title":"The epithelial danger signal IL-1\u03b1 is a potent activator of fibroblasts and reactivator of intestinal inflammation","volume":"185","author":"Scarpa","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0650","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2010.10.002","article-title":"Oral TNF-\u03b1 gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease","volume":"150","author":"Kriegel","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115242_bb0655","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1038\/s41467-022-33436-0","article-title":"In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115242_bb0660","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3748\/wjg.v28.i18.1922","article-title":"Novel drug delivery systems for inflammatory bowel disease","volume":"28","author":"Yasmin","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0665","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/ibd\/izz205","article-title":"Nanotechnology in the treatment of inflammatory bowel disease","volume":"25","author":"Giron","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0670","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00524","article-title":"Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors","volume":"11","author":"Hua","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0675","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.670124","article-title":"Orally administrable therapeutic nanoparticles for the treatment of colorectal cancer","volume":"9","author":"Ying","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0680","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbrc.2022.06.061","article-title":"Measurement of intraluminal pH changes in the gastrointestinal tract of mice with gastrointestinal diseases","volume":"620","author":"Sun","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2026.115242_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121707","article-title":"Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: a novel therapeutic solution to treat ulcerative colitis","volume":"288","author":"Sung","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115242_bb0690","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.biomaterials.2010.09.034","article-title":"Oral nuclear factor-kappaB decoy oligonucleotides delivery system with chitosan modified poly(D,L-lactide-co-glycolide) nanospheres for inflammatory bowel disease","volume":"32","author":"Tahara","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115242_bb0695","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1039\/C4TB00922C","article-title":"Calcium phosphate increases the encapsulation efficiency of hydrophilic drugs (proteins, nucleic acids) into poly(d,l-lactide-co-glycolide acid) nanoparticles for intracellular delivery","volume":"2","author":"Dordelmann","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.115242_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2024.03.005","article-title":"Unleashing the potential of oral deliverable nanomedicine in the treatment of inflammatory bowel disease","volume":"18","author":"Yang","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0705","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4014\/jmb.2203.03022","article-title":"Leaky gut in IBD: intestinal barrier-gut microbiota interaction","volume":"32","author":"Yu","year":"2022","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020484","article-title":"Advances in oral drug delivery systems: challenges and opportunities","volume":"15","author":"Lou","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115242_bb0715","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/156802612798919132","article-title":"Intracellular localization and routing of miRNA and RNAi pathway components","volume":"12","author":"Ohrt","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jconrel.2026.115242_bb0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-9798-5_1","article-title":"An overview of drug delivery systems","volume":"2059","author":"Jain","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114466","article-title":"Targeted therapeutics for IBD unraveling the potential of stimulus-responsive nanoparticles","volume":"389","author":"Barros","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115242_bb0730","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.nantod.2014.04.011","article-title":"Intracellular delivery of nanomaterials: how to catch endosomal escape in the act","volume":"9","author":"Martens","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2026.115242_bb0735","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2026.115242_bb0740","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-physiol-012110-142317","article-title":"Lysosomal acidification mechanisms","volume":"74","author":"Mindell","year":"2012","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0745","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jconrel.2012.05.020","article-title":"On the cellular processing of non-viral nanomedicines for nucleic acid delivery: mechanisms and methods","volume":"161","author":"Vercauteren","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115242_bb0750","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb0755","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2026.115242_bb0760","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.biomaterials.2013.01.033","article-title":"Multifunctional polymeric nanoparticles for oral delivery of TNF-alpha siRNA to macrophages","volume":"34","author":"He","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115242_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2025.100861","article-title":"Recent advances in engineering chitosan-based nanoplatforms in biotherapeutic multi-delivery for multi-targeted disease treatments: promises and outlooks","volume":"69","author":"Khorasani","year":"2025","journal-title":"Colloid Interface Sci. Commun."},{"key":"10.1016\/j.jconrel.2026.115242_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102322","article-title":"Highly efficient nucleic acid encapsulation method for targeted gene therapy using antibody conjugation system","volume":"35","author":"Hong","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.115242_bb0775","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2022.08.030","article-title":"Spheroplexes: hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA","volume":"350","author":"Arruda","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115242_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125109","article-title":"Incorporation of ionizable lipids into the outer shell of lipid-coated calcium phosphate nanoparticles boosts cellular mRNA delivery","volume":"670","author":"Khalifeh","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115242_bb0785","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2010.11.012","article-title":"Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles","volume":"150","author":"Giger","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115242_bb0790","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2015.12.021","article-title":"Colonic gene silencing using siRNA-loaded calcium phosphate\/PLGA nanoparticles ameliorates intestinal inflammation in vivo","volume":"222","author":"Frede","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115242_bb0795","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw5984","article-title":"MiRNA-loaded biomimetic nanoparticles orchestrate gut microbe to ameliorate inflammatory bowel disease","volume":"11","author":"Liu","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115242_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114175","article-title":"MiR-29a-loaded nanoparticles alleviate inflammatory bowel disease via Sgk1\/Foxo3a axis","volume":"387","author":"Niu","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.115242_bb0805","doi-asserted-by":"crossref","DOI":"10.1007\/s11051-020-04785-y","article-title":"Effect of particle size and surface charge of nanoparticles in penetration through intestinal mucus barrier","volume":"22","author":"Bandi","year":"2020","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb0810","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4155\/tde-2015-0002","article-title":"The properties of the mucus barrier, a unique gel--how can nanoparticles cross it?","volume":"7","author":"Pearson","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2026.115242_bb0815","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"PEGylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115242_bb0820","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1021\/acsnano.2c11147","article-title":"Mucus penetration of surface-engineered nanoparticles in various pH microenvironments","volume":"17","author":"Guo","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115242_bb0825","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1038\/s41467-025-63037-6","article-title":"Targeting intestinal inflammation using locked nucleic acids delivered via lipid nanoparticles","volume":"16","author":"Qassem","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115242_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030429","article-title":"Therapeutic targeting of intestinal fibrosis in Crohn\u2019s disease","volume":"11","author":"Santacroce","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.115242_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e40604","article-title":"TWISTed fibroblasts: new drivers of intestinal fibrosis in Crohn\u2019s disease","volume":"10","author":"Lovisa","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.115242_bb0840","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fphar.2019.00162","article-title":"The molecular mechanism of transforming growth factor-beta signaling for intestinal fibrosis: a mini-review","volume":"10","author":"Yun","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0845","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.gastro.2022.09.006","article-title":"Th17 cell-derived amphiregulin promotes colitis-associated intestinal fibrosis through activation of mTOR and MEK in intestinal myofibroblasts","volume":"164","author":"Zhao","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb0850","article-title":"Myeloid-derived suppressor cell accumulation drives intestinal fibrosis through mCCL6\/hCCL15 chemokine-mediated fibroblast activation","volume":"12","author":"Cheng","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.jconrel.2026.115242_bb0855","doi-asserted-by":"crossref","first-page":"2193115","DOI":"10.1080\/19490976.2023.2193115","article-title":"Crohn's disease-associated AIEC inhibiting intestinal epithelial cell-derived exosomal let-7b expression regulates macrophage polarization to exacerbate intestinal fibrosis","volume":"15","author":"Xu","year":"2023","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jconrel.2026.115242_bb0860","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2017.06.013","article-title":"Treatment of intestinal fibrosis in experimental inflammatory bowel disease by the pleiotropic actions of a local rho kinase inhibitor","volume":"153","author":"Holvoet","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb0865","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/ibd\/izaa169","article-title":"AXL is a potential target for the treatment of intestinal fibrosis","volume":"27","author":"Steiner","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0870","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179472","article-title":"TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn\u2019s disease","volume":"134","author":"Zhang","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115242_bb0875","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ibd\/izx008","article-title":"Inhibition of fibroblast activation protein restores a balanced extracellular matrix and reduces fibrosis in Crohn\u2019s disease strictures ex vivo","volume":"24","author":"Truffi","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0880","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/ecco-jcc\/jjac084","article-title":"CD147 targeting by AC-73 induces autophagy and reduces intestinal fibrosis associated with TNBS chronic colitis","volume":"16","author":"Butera","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.jconrel.2026.115242_bb0885","doi-asserted-by":"crossref","first-page":"i222","DOI":"10.1093\/ecco-jcc\/jjae190.0113","article-title":"DOP074 JAK inhibition to target fibroblasts and IBD-related fibrosis","volume":"19","author":"Su","year":"2025","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.jconrel.2026.115242_bb0890","doi-asserted-by":"crossref","first-page":"2544689","DOI":"10.1080\/10717544.2025.2544689","article-title":"Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems","volume":"32","author":"Lin","year":"2025","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115242_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120836","article-title":"Colon-targeted delivery of tacrolimus using pH-responsive polymeric nanoparticles for murine colitis therapy","volume":"606","author":"Cai","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115242_bb0900","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1039\/D4TB02868F","article-title":"Precision therapeutics for inflammatory bowel disease: advancing ROS-responsive nanoparticles for targeted and multifunctional drug delivery","volume":"13","author":"Wan","year":"2025","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.115242_bb0905","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.biomaterials.2019.05.012","article-title":"Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis","volume":"212","author":"Gou","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115242_bb0910","first-page":"3077","article-title":"Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP\/HSA MNPs) in vivo","volume":"6","author":"Tang","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.115242_bb0915","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4028\/www.scientific.net\/JNanoR.27.75","article-title":"Antheraea pernyi silk fibroin nanoparticles for drug delivery","volume":"27","author":"Lu","year":"2014","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.04.016","article-title":"Prevention of diabetes-associated fibrosis: strategies in FcRn-targeted nanosystems for oral drug delivery","volume":"175","author":"Azevedo","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.115242_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121937","article-title":"ROS-triggered self-disintegrating and pH-responsive astaxanthin nanoparticles for regulating the intestinal barrier and colitis","volume":"292","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115242_bb0930","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nmat2859","article-title":"Orally delivered thioketal nanoparticles loaded with TNF-alpha-siRNA target inflammation and inhibit gene expression in the intestines","volume":"9","author":"Wilson","year":"2010","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115242_bb0935","doi-asserted-by":"crossref","first-page":"24404","DOI":"10.1021\/acsnano.3c11089","article-title":"Orally administrated inflamed colon-targeted nanotherapeutics for inflammatory bowel disease treatment by oxidative stress level modulation in colitis","volume":"17","author":"Min","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.115242_bb0940","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1039\/D3TB02302H","article-title":"Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances","volume":"12","author":"Hu","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.115242_bb0945","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.3390\/nu16213633","article-title":"Phytochemical compounds as promising therapeutics for intestinal fibrosis in inflammatory bowel disease: a critical review","volume":"16","author":"Touny","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.jconrel.2026.115242_bb0950","doi-asserted-by":"crossref","first-page":"10064","DOI":"10.1038\/s41598-019-46472-6","article-title":"Fibrogenesis in chronic DSS colitis is not influenced by neutralisation of regulatory T cells, of major T helper cytokines or absence of IL-13","volume":"9","author":"Creyns","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115242_bb0955","doi-asserted-by":"crossref","first-page":"G786","DOI":"10.1152\/ajpgi.00059.2012","article-title":"Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease","volume":"303","author":"Rieder","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0960","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/00001574-200107000-00004","article-title":"Intestinal fibrosis in human and experimental inflammatory bowel disease","volume":"17","author":"Lund","year":"2001","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.jconrel.2026.115242_bb0965","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2007.11.059","article-title":"Microbial influences in inflammatory bowel diseases","volume":"134","author":"Sartor","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb0970","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1053\/j.gastro.2007.12.043","article-title":"Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis","volume":"134","author":"Grassl","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb0975","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5217\/ir.2019.09148","article-title":"Fibrostenotic strictures in Crohn\u2019s disease","volume":"18","author":"Yoo","year":"2020","journal-title":"Intest. Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb0980","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/cells9030775","article-title":"Pirfenidone inhibits cell proliferation and collagen I production of primary human intestinal fibroblasts","volume":"9","author":"Cui","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.115242_bb0985","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ibd\/izz115","article-title":"Decellularized human gut as a natural 3D platform for research in intestinal fibrosis","volume":"25","author":"Giuffrida","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0990","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ibd\/izab166","article-title":"Effect of ABT-263 on intestinal fibrosis in human myofibroblasts, human intestinal organoids, and the mouse salmonella typhimurium model","volume":"28","author":"Johnson","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jconrel.2026.115242_bb0995","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1053\/j.gastro.2021.01.131","article-title":"Development of a personalized model of intestinal fibrosis using human intestinal organoids derived from induced pluripotent stem cells","volume":"160","author":"Estrada","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2026.115242_bb1000","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00011-024-01901-9","article-title":"Characterization of patient-derived intestinal organoids for modelling fibrosis in Inflammatory Bowel Disease","volume":"73","author":"Laudadio","year":"2024","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.jconrel.2026.115242_bb1005","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9929461","article-title":"Development of a human intestinal organoid model for in vitro studies on gut inflammation and fibrosis","volume":"2021","author":"Kandilogiannakis","year":"2021","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jconrel.2026.115242_bb1010","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/s41598-017-02190-5","article-title":"Organoid-based epithelial to mesenchymal transition (OEMT) model: from an intestinal fibrosis perspective","volume":"7","author":"Hahn","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115242_bb1015","series-title":"Drug Delivery Aspects","first-page":"57","article-title":"Large-scale manufacturing of nanoparticles\u2014an industrial outlook","author":"Shegokar","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115242_bb1020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040701","article-title":"Progress in drug delivery systems based on nanoparticles for improved glioblastoma therapy: addressing challenges and investigating opportunities","volume":"17","author":"Rahman","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115242_bb1025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejpb.2023.10.006","article-title":"The mixing method used to formulate lipid nanoparticles affects mRNA delivery efficacy and organ tropism","volume":"192","author":"Strelkova Petersen","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.115242_bb1030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2026.115242_bb1035","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1039\/D5NA00603A","article-title":"Flame-made nanoparticles for magnetic hyperthermia and MRI in colorectal cancer theranostics","volume":"7","author":"Zhang","year":"2025","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.jconrel.2026.115242_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.pecs.2025.101272","article-title":"Biomedical applications of nanoparticles made by flame spray pyrolysis","volume":"113","author":"Li","year":"2026","journal-title":"Prog. Energy Combust. Sci."},{"key":"10.1016\/j.jconrel.2026.115242_bb1045","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2026.1735885","article-title":"Regulatory framework for polymer-based nanotherapeutics in clinical translation","volume":"14","author":"Stucchi","year":"2026","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115242_bb1050","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1125577","article-title":"A. Scientific Advisory Board of the regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products","volume":"11","author":"Oualikene-Gonin","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.jconrel.2026.115242_bb1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2025.107119","article-title":"Immunonutrients as modulators of inflammation, barrier integrity, and immune regulation: toward precision nutrition","volume":"136","author":"Dalimunthe","year":"2026","journal-title":"J. Funct. Foods"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:55:58Z","timestamp":1790211358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926006462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":211,"alternative-id":["S0168365926006462"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115242","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoengineered RNA delivery systems for gene therapy in intestinal fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115242"}}